Literature DB >> 19945798

Ablation of benign prostatic hyperplasia using microbubble-mediated ultrasound cavitation.

Tao Li1, Zheng Liu.   

Abstract

Benign prostatic hyperplasia (BPH) is a world-wide common disease in elderly male patients. A number of invasive physiotherapies have been used to replace prostatectomy. In this article we report our hypothesis of using microbubbles-mediated ultrasound cavitation effects to ablate prostatic tissues. Microbubble ultrasound contrast agent is widely used contrast media in ultrasonography, yet it is also found to act as cavitation nuclei or enhancer. Once excited by a high peak pressure ultrasound pulse, the mechanical effects, like shock wave and microstream, released from cavitation could produce a series of bioeffects, contributing to sonoporation, microvascular rupture and hematoma. BPH is known to have hyperplastic neovasculature and this make it possible to be disrupted by the physical effects of cavitation under existing microbubbles in circulation. Mechanical ablation of prostatic capillary or small vessels could result in pathological alterations such as thrombosis, micro-circulation blockage, prostatic necrosis and atrophia. Thereupon it could effectively treat BPH by nontraumatic ways. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945798     DOI: 10.1016/j.mehy.2009.10.052

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  Effects of low-frequency ultrasound combined with microbubbles on benign prostate hyperplasia.

Authors:  Shao-Ling Yang; Ke-Qiang Tang; Wen-Kun Bai; E Shen; Yi-Wen Zhao; Yan-Duan Lin; Shu-Liang Nan; Hu Bing
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

2.  Combined low-frequency ultrasound and microbubble contrast agent for the treatment of benign prostatic hyperplasia.

Authors:  Shao-ling Yang; Ke-qiang Tang; Wen-kun Bai; Yi-Wen Zhao; E Shen; Jun-jia Tao; Bing Hu
Journal:  J Endourol       Date:  2013-08       Impact factor: 2.942

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.